China Pharma price to sales ratio CPHI

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 7.2×
9-year median: 1.1×
Against its 9-year history: 96th; percentile: 0 is its lowest day, 100 its highest
9-year range: 0.1× to 15.4×
Peer median: 0.4×

China Pharma's price to sales ratio is 7.2× as of Oct 23, 2026.

That is above its 9-year median of 1.1×, higher than on 96% of days in the last 9 years.

Over that time it ranged from 0.1× in Nov 2023 to 15.4× in Jul 2026.

The median for 4 large drugmakers of a similar size is 0.4×.

Price to sales ratio over time

median 1.1×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.2×	0.7×	15.4×
2025	1.6×	0.7×	2.1×
2024	0.7×	0.3×	0.8×
2023	0.5×	0.1×	0.7×
2022	0.6×	0.6×	2.4×
2021	2.4×	2.1×	4.5×
2020	1.8×	1.1×	3.3×
2019	1.0×	0.8×	1.4×
2018	0.7×	0.6×	1.5×
2017	0.5×	0.5×	0.6×
2016	0.4×	0.3×	0.4×
2015	0.3×	0.3×	0.7×
2014	0.6×	0.3×	0.7×
2013	0.3×	0.2×	0.3×
2012	0.2×	0.1×	0.2×

Against its peers

Companies in Drug Manufacturers - General nearest China Pharma's size, closest first, today.

Company	Price to sales ratio
CPHIChina Pharma	7.2×
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
Peer median	0.4×

Where China Pharma ranks

#95of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on China Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.